China Isotope & Radiation Corporation (HKG:1763)
13.26
-0.23 (-1.70%)
Sep 11, 2026, 9:40 AM HKT
China Isotope & Radiation Revenue
China Isotope & Radiation had revenue of 2.99B CNY in the half year ending June 30, 2026, with 6.53% growth. This brings the company's revenue in the last twelve months to 7.31B, down -4.18% year-over-year. In the year 2025, China Isotope & Radiation had annual revenue of 7.19B, down -5.11%.
Revenue (ttm)
7.31B CNY
Revenue Growth
-4.18%
P/S Ratio
0.51
Revenue / Employee
2.04M CNY
Employees
3,578
Market Cap
4.32B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.19B | -387.10M | -5.11% |
| Dec 31, 2024 | 7.57B | 939.76M | 14.16% |
| Dec 31, 2023 | 6.63B | 481.44M | 7.82% |
| Dec 31, 2022 | 6.15B | 1.01B | 19.63% |
| Dec 31, 2021 | 5.14B | 869.51M | 20.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Modern Dental Group | 3.93B |
| AK Medical Holdings | 1.79B |
| LifeTech Scientific | 1.49B |
| Zylox-Tonbridge Medical Technology | 1.39B |
| Beijing Chunlizhengda Medical Instruments | 1.13B |
| MicroTech Medical (Hangzhou) | 957.05M |
| Peijia Medical | 905.10M |
| MicroPort NeuroScientific | 879.66M |
China Isotope & Radiation News
- 13 days ago - China Isotope & Radiation Earnings release: H1 2026 - Filings
- 13 days ago - China Isotope & Radiation Quarterly report: H1 2026 - Filings
- 5 months ago - China Isotope & Radiation Earnings release: H2 2025 - Filings
- 5 months ago - China Isotope & Radiation Annual report: H2 2025 - Filings